Roth Capital Starts Vascular Biogenics Ltd (VBLT) at Buy

Roth Capital initiates coverage on Vascular Biogenics Ltd (NASDAQ: VBLT) with a Buy rating and a price target of $13.00.

Analyst Joseph Pantginis commented, "VBLT is a clinical stage biotechnology company with two technology platforms targeting oncology and immunology indications. The first platform is Vascular Targeting System (VTS), which is a multi-component gene therapy design targeting vascular endothelial cells. The second platform is comprised of lecinoxoids, which are synthetic oxidized phospholipid small molecules mimicking naturally occurring anti-inflammatory agents in the body."

For an analyst ratings summary and ratings history on Vascular Biogenics Ltd click here. For more ratings news on Vascular Biogenics Ltd click here.

Shares of Vascular Biogenics Ltd closed at $5.05 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Morgan Stanley Assumes Bumble Inc. (BMBL) at Equalweight
• B.Riley Starts Energy Fuels (UUUU) at Buy